Skip to main content
Home/Resources/Agentic AI Future Vision
Industry TrendsOct 15, 202515 min read

Agentic AI in Regulatory Affairs: The Future Vision

The pharmaceutical industry stands at the threshold of a profound transformation. As AI systems evolve from assistive tools to fully autonomous agents, regulatory operations will fundamentally change. This is the future of regulatory affairs.

DA
DossiAIr Research Team
AI & Regulatory Innovation

For decades, pharmaceutical regulatory affairs has been one of the most labor-intensive, expert-dependent functions in the industry. The preparation of a single regulatory submission can involve hundreds of professionals working for 18-24 months, coordinating across disciplines, geographies, and organizational boundaries.

Today's AI systems are beginning to assist with discrete tasks—extracting data from PDFs, suggesting document classifications, checking compliance against known rules. But this is just the beginning. The next evolution of AI will not merely assist; it will operate autonomously as an agentic system.

This article explores the trajectory from assistive AI to fully agentic AI in pharmaceutical regulatory operations, examining the technological foundations, organizational implications, and transformative potential of this inevitable evolution.

What is Agentic AI?

Agentic AI refers to artificial intelligence systems that can pursue complex goals autonomously with minimal human intervention. Unlike traditional AI that responds to individual prompts or queries, agentic AI systems can:

Core Characteristics of Agentic AI

1. Goal-Directed Autonomy

Given a high-level objective, the system determines its own approach, breaks down tasks, and executes multi-step workflows without step-by-step human guidance

2. Dynamic Planning

Ability to create, adjust, and optimize execution plans based on emerging information, obstacles, or changing requirements

3. Tool Use

Capability to invoke external tools, APIs, databases, and systems as needed to accomplish objectives

4. Self-Correction

Recognition of errors or suboptimal approaches and autonomous adjustment of strategy without human intervention

5. Long-Context Coherence

Maintaining consistency and logical coherence across extended workflows spanning days, weeks, or months

In the context of regulatory affairs, an agentic AI system wouldn't just extract a table from a PDF when asked. It would understand that a Module 2.3 Quality Summary requires stability data, locate the relevant stability studies across the organization's document repositories, extract and format the data appropriately, cross-check against ICH guidelines, generate compliant narrative text, create cross-references, validate the output, and integrate it into the submission—all from a single high-level instruction.

The Evolution from Assistive to Agentic AI

The journey toward agentic AI in regulatory affairs progresses through distinct stages, each building on the capabilities of the previous.

1

Stage 1: Basic Automation

Rule-based systems and simple automation

Capabilities

  • • Automated file organization and naming
  • • Template-based document generation
  • • Simple OCR text extraction
  • • Basic validation rule checking

Human Role

  • • Manual content creation
  • • All decision-making
  • • Quality control and validation
  • • 95%+ of intellectual work

Impact: Minimal - primarily administrative time savings

2

Stage 2: Assistive AI

Machine learning and early LLM applications

Capabilities

  • • Intelligent document classification
  • • Table/chart extraction from PDFs
  • • Text generation from prompts
  • • Pattern-based cross-referencing
  • • Compliance checking against guidelines

Human Role

  • • Prompt engineering and guidance
  • • Review and approval of AI output
  • • Workflow orchestration
  • • Complex decision-making
  • • 60-70% of intellectual work

Impact: Moderate - 30-50% time savings on specific tasks, human-in-the-loop required

3

Stage 3: Collaborative Agents

Multi-step workflows with human collaboration

Capabilities

  • • Autonomous completion of entire modules
  • • Dynamic fetching of source materials
  • • Self-correction and quality improvement
  • • Cross-module dependency management
  • • Proactive compliance monitoring

Human Role

  • • High-level goal setting
  • • Strategic decision checkpoints
  • • Exception handling
  • • Final quality oversight
  • • 20-30% of intellectual work

Impact: Substantial - 70-80% time savings, humans focus on oversight and strategy

4

Stage 4: Fully Agentic Systems

End-to-end autonomous regulatory operations

Capabilities

  • • Fully autonomous submission preparation
  • • Real-time regulatory intelligence monitoring
  • • Predictive compliance analysis
  • • Automatic adaptation to regulation changes
  • • Multi-agency submission optimization
  • • Continuous lifecycle management

Human Role

  • • Setting organizational priorities
  • • Handling novel/unprecedented situations
  • • Regulatory strategy development
  • • Stakeholder relationships
  • • 5-10% of intellectual work

Impact: Transformative - 90%+ automation, humans shift to pure strategy and governance

Technological Foundations Enabling Agentic AI

The emergence of agentic AI in regulatory affairs depends on several converging technological capabilities:

🧠Advanced Reasoning Models

Large language models with enhanced reasoning capabilities (e.g., chain-of-thought, tree-of-thoughts, constitutional AI) can break down complex regulatory requirements into actionable steps.

Example Application:

An AI system receives the instruction "Prepare Module 3.2.P.8 for FDA NDA submission." It autonomously: (1) retrieves ICH M4Q guidance, (2) identifies required stability data points, (3) locates relevant stability studies, (4) extracts data in compliance with 21 CFR guidelines, (5) generates narrative following FDA preferences, (6) creates cross-references, (7) validates output, and (8) flags uncertainties for human review.

🔗Function Calling & Tool Use

Modern AI systems can invoke external tools, APIs, and databases dynamically based on task requirements. This capability—known as function calling or tool use—is fundamental to agentic behavior.

Regulatory Applications:

  • • Query internal document management systems (EDMS)
  • • Fetch regulatory intelligence from FDA, EMA databases
  • • Invoke eCTD validation tools and parse results
  • • Trigger notification systems for stakeholder updates
  • • Access clinical trial databases for study data

🎯Planning & Orchestration Frameworks

Agentic systems require sophisticated planning algorithms that can decompose high-level goals into executable sub-tasks, manage dependencies, and adapt to changing conditions.

Techniques:

  • ReAct (Reasoning + Acting): Interleaving reasoning traces with actions
  • Plan-and-Execute: Creating comprehensive plans before execution
  • Reflection: Self-critique and iterative improvement
  • Multi-agent collaboration: Specialized agents for different regulatory domains

🗄️Long-Context Memory & Retrieval

Regulatory submissions span thousands of pages across hundreds of documents. Agentic AI systems must maintain coherent understanding across this vast information space.

Enabling Technologies:

  • • Extended context windows (100K-1M+ tokens)
  • • Retrieval-augmented generation (RAG) for selective information access
  • • Vector databases for semantic similarity search
  • • Knowledge graphs capturing regulatory ontologies

Agentic AI Use Cases in Regulatory Affairs

As agentic AI systems mature, they will transform every aspect of regulatory operations:

1Autonomous Submission Preparation

Complete end-to-end preparation of regulatory submissions with minimal human intervention

Autonomous Workflow:

  1. 1.Receive high-level instruction: "Prepare FDA NDA for Product X"
  2. 2.Analyze regulatory requirements for Product X therapeutic area
  3. 3.Fetch all relevant source documents from enterprise systems
  4. 4.Generate all required modules (1-5) following ICH M4 structure
  5. 5.Create cross-references and hyperlinks automatically
  6. 6.Validate against FDA eCTD specifications
  7. 7.Flag ambiguities or missing data for human review
  8. 8.Assemble final submission package ready for filing

Projected Impact: 18-24 months → 2-4 weeks for initial draft

2Continuous Regulatory Intelligence

Real-time monitoring and proactive adaptation to regulatory landscape changes

Autonomous Workflow:

  1. 1.Monitor FDA, EMA, PMDA, and other agency websites 24/7
  2. 2.Detect new guidance documents, rule changes, precedent decisions
  3. 3.Analyze impact on in-flight and future submissions
  4. 4.Automatically update internal regulatory requirements database
  5. 5.Alert relevant stakeholders with contextualized summaries
  6. 6.Suggest submission strategy adjustments based on new intelligence
  7. 7.Update document templates and compliance checklists proactively

Projected Impact: Zero latency between regulation change and organizational awareness

3Multi-Agency Submission Optimization

Simultaneous optimization of submission content for multiple regulatory agencies

Autonomous Workflow:

  1. 1.Maintain single source of truth for product data
  2. 2.Automatically generate FDA, EMA, PMDA-specific variants
  3. 3.Optimize content for each agency's preferences and requirements
  4. 4.Manage Module 1 region-specific variations (forms, labels)
  5. 5.Ensure consistency across common sections (Modules 2-5)
  6. 6.Track submission status across all agencies
  7. 7.Coordinate responses to agency questions across regions

Projected Impact: Parallel global submissions instead of sequential regional filings

4Predictive Deficiency Prevention

Anticipating and preventing submission deficiencies before filing

Autonomous Workflow:

  1. 1.Analyze historical deficiency data across similar products/indications
  2. 2.Identify high-risk sections based on agency trends
  3. 3.Compare draft submission against precedent approvals
  4. 4.Predict likely information requests or deficiency areas
  5. 5.Proactively strengthen weak sections
  6. 6.Generate pre-emptive rationales for anticipated questions
  7. 7.Validate all technical requirements comprehensively

Projected Impact: Reduce Refuse-to-File and major deficiency rates by 60-80%

5Lifecycle Maintenance Automation

Autonomous management of post-approval variations, supplements, and renewals

Autonomous Workflow:

  1. 1.Monitor product changes (manufacturing, formulation, labeling)
  2. 2.Determine regulatory classification (Type I, II variations)
  3. 3.Automatically prepare variation applications
  4. 4.Track approval status across all marketed regions
  5. 5.Update product information documents (SmPC, labels)
  6. 6.Maintain regulatory compliance calendar
  7. 7.Prepare renewal submissions proactively

Projected Impact: Near-zero regulatory staff time for routine variations

Challenges on the Path to Agentic AI

While the vision of fully agentic AI in regulatory affairs is compelling, significant challenges remain:

⚖️Regulatory Acceptance & Validation

Concerns

  • • Regulatory agencies have not yet issued guidance on AI-generated submissions
  • • Questions about accountability and traceability
  • • Validation requirements for AI systems under GxP
  • • Audit trail and reproducibility expectations

Path Forward

  • • Industry working groups developing best practices
  • • Computer System Validation (CSV) frameworks for AI
  • • Transparent logging of AI decision-making
  • • Phased adoption with human oversight

🎯Accuracy, Reliability & Hallucinations

Challenges

  • • LLMs can generate plausible but incorrect information
  • • Regulatory submissions require 100% factual accuracy
  • • Edge cases and novel situations remain difficult
  • • Confidence calibration is imperfect

Mitigation Strategies

  • • Multi-model consensus voting
  • • Retrieval-augmented generation (RAG) for factual grounding
  • • Automated cross-verification against source documents
  • • Human review of high-risk sections

🔒Data Security & Confidentiality

Risks

  • • Proprietary clinical data exposure to AI providers
  • • Intellectual property leakage concerns
  • • Cloud vs. on-premise deployment trade-offs
  • • Cross-contamination between client projects (CRO context)

Solutions

  • • On-premise or private cloud AI deployments
  • • Zero-retention policies with AI providers
  • • Product/client isolation architectures
  • • Federated learning for model training

👥Organizational Change Management

Human Factors

  • • Workforce reskilling and transition
  • • Resistance from regulatory professionals
  • • Trust-building with AI-generated content
  • • Redefining roles and career paths

Change Strategies

  • • Gradual adoption with demonstrated value
  • • Upskilling programs for AI collaboration
  • • Shift focus to strategic/oversight roles
  • • Clear accountability frameworks

The Evolving Human Role in an Agentic Future

As AI systems become increasingly autonomous, the role of human regulatory professionals will not disappear—it will transform. The future regulatory professional will focus on:

🎯

Strategic Regulatory Planning

Determining optimal regulatory pathways, agency selection, and market entry strategies based on business objectives rather than document preparation

🛡️

AI Oversight & Governance

Establishing validation frameworks, monitoring AI system performance, auditing outputs, and ensuring compliance with evolving AI regulations

💡

Novel Situation Handling

Addressing unprecedented regulatory scenarios, first-in-class products, and complex scientific/ethical questions beyond AI training data

🤝

Agency Relationship Management

Building and maintaining relationships with regulatory authorities, participating in pre-submission meetings, and navigating political/cultural nuances

📊

Continuous Improvement

Analyzing AI performance data, identifying improvement opportunities, and guiding evolution of regulatory AI systems based on real-world outcomes

🔗

Cross-Functional Coordination

Aligning regulatory strategy with R&D, commercial, medical affairs, and manufacturing functions to ensure organizational coherence

The Value Shift

In the agentic AI future, regulatory professionals will shift from execution to orchestration, from creation to curation, and from documentation to direction. The skills that will matter most are strategic thinking, judgment, creativity, stakeholder management, and ethical reasoning—precisely the capabilities that remain uniquely human.

Evolution Pathway to Fully Agentic Regulatory AI

Based on current technological trajectories and regulatory industry adoption patterns, the evolution toward fully agentic AI in pharmaceutical regulatory affairs will progress through distinct phases:

Phase 1: Early Adoption

Assistive AI becomes mainstream

30-40%
AI-enabled
  • Widespread adoption of AI for document classification, table extraction, and text generation
  • First regulatory submissions with significant AI-generated content
  • Industry working groups establish AI validation frameworks
  • Major pharma companies pilot multi-step AI workflows for specific modules

Phase 2: Collaborative Agents Emerge

Multi-step autonomous workflows

60-70%
AI-enabled
  • AI systems capable of autonomous completion of entire submission modules
  • Dynamic tool use and API integration becomes standard
  • First regulatory guidance on AI-generated submissions published
  • CROs offer AI-powered regulatory services at scale
  • Human-in-the-loop remains mandatory for quality oversight

Phase 3: Transition to Autonomy

End-to-end submission automation

80-85%
AI-enabled
  • First end-to-end AI-prepared submissions filed and approved
  • Regulatory agencies develop technical standards for AI validation
  • Multi-agent systems coordinate across entire submission lifecycle
  • Real-time regulatory intelligence monitoring becomes ubiquitous
  • Workforce transition accelerates; regulatory roles redefined

Phase 4: Fully Agentic Era

Autonomous regulatory operations

90%+
AI-enabled
  • Autonomous regulatory operations become industry standard
  • AI systems manage complete product lifecycle from IND through post-marketing
  • Submission times measured in weeks instead of months/years
  • Human regulatory professionals focus entirely on strategy and oversight
  • New regulatory paradigms emerge optimized for AI-to-AI interactions

Conclusion: Embracing the Agentic Future

The evolution from assistive to agentic AI in pharmaceutical regulatory affairs is not a question of if, but when. The technological foundations are being laid today. The business case is overwhelming. The competitive pressure is mounting.

Organizations that embrace this transformation early will gain substantial advantages: faster time-to-market, lower operational costs, higher quality submissions, and the ability to scale regulatory capacity without proportional increases in headcount. Those that resist will find themselves at a growing disadvantage as agentic AI systems become the industry standard.

The path forward requires thoughtful implementation—balancing innovation with validation, automation with oversight, efficiency with quality. But the destination is clear: a future where AI agents handle the vast majority of regulatory execution, freeing human expertise to focus on strategy, judgment, and the uniquely human elements of regulatory affairs.

Key Implications for the Industry

  • 1Regulatory submission timelines will compress from 18-24 months to 2-4 weeks
  • 2The limiting factor will shift from human capacity to data availability and quality
  • 3Regulatory professionals will transition to strategic, oversight, and governance roles
  • 4Small biotechs will have regulatory capabilities previously available only to large pharma
  • 5Global multi-agency submissions will become standard practice, not aspirational
  • 6The regulatory function will become a competitive differentiator based on AI maturity

Explore the Path to Agentic Regulatory AI

The future of regulatory affairs is being built today. Stay ahead of the transformation with insights, tools, and technologies designed for the agentic AI era.